Andrew Dahl Sells 544 Shares of Edwards Lifesciences (NYSE:EW) Stock

Edwards Lifesciences Corporation (NYSE:EW) SVP Andrew Dahl sold 544 shares of the firm’s stock in a transaction on Monday, August 31st. The stock was sold at an average price of $91.06, for a total value of $49,536.64. Following the completion of the sale, the senior vice president directly owned 14,868 shares of the company’s stock, valued at $1,353,880.08. The trade was a 3.53% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Edwards Lifesciences Stock Up 0.0%

Shares of EW stock opened at $90.78 on Wednesday. The stock’s fifty day moving average price is $89.71 and its 200 day moving average price is $85.26. Edwards Lifesciences Corporation has a 1-year low of $72.30 and a 1-year high of $96.29. The company has a market cap of $52.27 billion, a price-to-earnings ratio of 52.17, a price-to-earnings-growth ratio of 2.38 and a beta of 0.85. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.74 by $0.04. The company had revenue of $1.74 billion during the quarter, compared to analysts’ expectations of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The firm’s revenue was up 13.6% compared to the same quarter last year. During the same period last year, the business posted $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, research analysts expect that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Edwards Lifesciences

Hedge funds and other institutional investors have recently bought and sold shares of the business. Corient Private Wealth LP raised its position in Edwards Lifesciences by 1,028.9% during the 2nd quarter. Corient Private Wealth LP now owns 250,101 shares of the medical research company’s stock worth $22,624,000 after buying an additional 227,947 shares during the last quarter. HighTower Advisors LLC boosted its holdings in shares of Edwards Lifesciences by 1.4% in the 2nd quarter. HighTower Advisors LLC now owns 149,485 shares of the medical research company’s stock valued at $13,522,000 after acquiring an additional 2,101 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in shares of Edwards Lifesciences in the second quarter worth $61,441,000. Vancity Investment Management Ltd increased its stake in shares of Edwards Lifesciences by 15.8% in the second quarter. Vancity Investment Management Ltd now owns 167,876 shares of the medical research company’s stock worth $15,186,000 after acquiring an additional 22,881 shares during the period. Finally, California State Teachers Retirement System increased its stake in shares of Edwards Lifesciences by 9,187.8% in the second quarter. California State Teachers Retirement System now owns 80,962,062 shares of the medical research company’s stock worth $7,323,828,000 after acquiring an additional 80,090,362 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the stock. UBS Group assumed coverage on shares of Edwards Lifesciences in a research note on Tuesday, July 28th. They issued a “buy” rating and a $110.00 target price for the company. Wall Street Zen cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Saturday, July 4th. Citigroup lifted their price objective on shares of Edwards Lifesciences from $101.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th. Mizuho boosted their price objective on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the company an “outperform” rating in a report on Wednesday, July 15th. Finally, Royal Bank Of Canada upped their target price on Edwards Lifesciences from $100.00 to $110.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. Seventeen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, Edwards Lifesciences has a consensus rating of “Moderate Buy” and a consensus target price of $100.27.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.